EAST RUTHERFORD, N.J.,
May 29, 2014 /PRNewswire/
-- Cambrex Corporation (NYSE: CBM, "Cambrex") announced
today that James F. Winschel, Jr.,
age 64, was appointed to the Company's Board of Directors for a
term expiring on the date of its 2015 annual meeting and will serve
on the Board's Audit Committee and Regulatory Affairs
Committee. Mr. Winschel's appointment maintains the size of
the Board at nine members following John
Miller's retirement in April.
Chairman of the Board, Shlomo
Yanai, commented, "Jim has enjoyed a distinguished business
career and his appointment further strengthens our functional
expertise and life sciences experience on the Board. I am
confident that he will make significant contributions to our
company."
Following thirteen years as Senior Vice President and Chief
Financial Officer of PAREXEL International Corporation (NASDAQ:
PRXL), a leading biopharmaceutical services organization providing
comprehensive drug development, consulting, medical communications,
and technology services and solutions to the biopharmaceutical
industry in over 100 countries, Mr. Winschel was named Executive
Vice President of PAREXEL in September 2013.
As CFO of PAREXEL, Mr. Winschel was responsible for directing
all worldwide financial and related matters. Since joining
PAREXEL in June 2000, PAREXEL's
revenue has grown by more than $1.5
billion, backlog has increased by $4.5 billion, and PAREXEL's market capitalization
went from $225 million to
$2.8 billion.
Prior to joining PAREXEL, Mr. Winschel served as President of
U.B. Vehicle Leasing, Inc., a division of BTM Capital Corporation,
a subsidiary of The Bank of Tokyo-Mitsubishi, Ltd. Prior to
assuming the presidency of this division, he served as Executive
Vice President and CFO of BTM Capital. Previously, Mr.
Winschel held leadership positions at Caremark International, Inc.,
Whirlpool Financial Corporation, and the General Electric
Company.
About Cambrex
Cambrex Corporation is an innovative
life sciences company that provides products, services and
technologies to accelerate the development and commercialization of
small molecule therapeutics. The Company offers Active
Pharmaceutical Ingredients (APIs), advanced intermediates and
enhanced drug delivery products for branded and generic
pharmaceuticals. Development and manufacturing capabilities include
enzymatic biotransformations, high potency APIs, high energy
chemical synthesis, controlled substances and formulation of
finished dosage form products. For more information, please
visit www.cambrex.com.
SOURCE Cambrex Corporation